Intellectual Property Law and Copyright Laws

The Intellectual Property Enterprise Court has ruled that combining descriptive words like "flower" and "box" does not automatically create a descriptive trade mark, finding FLOWERBX valid and infringed by a competitor's similar branding. The decision demonstrates how strong evidence of brand recognition and actual consumer confusion can be decisive in trade mark enforcement cases, particularly in the context of online retail where visual similarity carries significant weight.

M&S and Sephora have launched an exciting brand collaboration that brings together two highly recognisable retail names. Beyond the consumer appeal, this partnership raises important questions about trade mark licensing, co-branding arrangements, and how both parties maintain control over their valuable brand assets throughout the collaboration.

Trade marks require genuine commercial use to maintain protection, but what constitutes "genuine use" in practice? Recent high-profile disputes, including X's battle over the Twitter brand, reveal how corporate rebrands and strategic shifts can expose even world-famous marks to revocation challenges. Understanding the nuances of use requirements and maintaining proper evidence has become critical for brand owners navigating M&A activity, product discontinuations, or market expansions.

M&S and Sephora have launched an exciting brand collaboration that brings together two highly recognisable retail names. Beyond the consumer appeal, this partnership raises important questions about trade mark licensing, co-branding arrangements, and how both parties maintain control over their valuable brand assets throughout the collaboration.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

For many medical technology companies, a patent is the natural starting point when considering intellectual property protection for a new product.

How is artificial intelligence transforming the creative industries, and what skills will designers need to thrive in an AI-driven future? Industry experts from tangerine, terrible*, The Frank Co., and Cleo explore the evolving relationship between AI, sustainability, and human-centered design in this thought-provoking discussion recorded at the London Design Festival.

An intellectual property lawyer helps businesses protect, register, commercialise and enforce their ideas, brands, products and creative assets. Good advice works in two directions: it helps a business stay on the right side of existing rights and avoid attracting claims, while also shaping its own portfolio so it becomes defensible, valuable and enforceable.

As AI voice cloning technology becomes increasingly sophisticated and accessible, the Save Our Voices Now campaign calls for statutory rights allowing individuals to own and control their voice as intellectual property. This article examines whether existing UK law sufficiently protects one of our most personal and recognisable attributes, exploring copyright, trade marks, passing off, and the practical steps individuals and businesses can take.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

As computational biology and artificial intelligence reshape drug discovery, pharmaceutical companies face a critical challenge: how to protect not just the final therapeutic compound, but the entire ecosystem of datasets, models, and biological insights that enabled its creation. This article examines the evolving intellectual property landscape where 90% of clinical candidates still fail, yet the tools predicting their success are becoming as valuable as the medicines themselves.

The European Health Data Space (EHDS) regulation has entered into force, creating a harmonised framework for cross-border health data access across the EU. While Europe possesses exceptional health data resources—particularly in Nordic countries with comprehensive patient registries—it has historically lacked the commercial data market infrastructure seen in the United States. This analysis explores how life science companies and investors can position themselves to capitalise on emerging opport